Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A Proliferation-Inducing Ligand (APRIL), also known as TNFSF13 or CD256, is a member of the tumor necrosis factor (TNF) ligand superfamily. It promotes B cell survival, immunoglobulin class switching, and has been implicated in autoimmune diseases and cancer. APRIL interacts primarily with BCMA, TACI, and Heparan Sulfate Proteoglycans (HSPGs).
Inhibition of APRIL reduces proteinuria and slows kidney disease progression in IgA nephropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on A Proliferation-Inducing Ligand (APRIL).